These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12369885)

  • 1. Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases.
    Thompson AJ; Barrow CJ
    Curr Med Chem; 2002 Oct; 9(19):1751-62. PubMed ID: 12369885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of amyloid fibril formation.
    Dovidchenko NV; Leonova EI; Galzitskaya OV
    Biochemistry (Mosc); 2014 Dec; 79(13):1515-27. PubMed ID: 25749162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein aggregation as a cause for disease.
    Scheibel T; Buchner J
    Handb Exp Pharmacol; 2006; (172):199-219. PubMed ID: 16610361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.
    Moreno-Gonzalez I; Soto C
    Semin Cell Dev Biol; 2011 Jul; 22(5):482-7. PubMed ID: 21571086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins.
    Marrero-Winkens C; Sankaran C; Schätzl HM
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32927676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heparan sulphates, amyloidosis and neurodegeneration].
    Vera C; Alvarez-Orozco JA; Maiza A; Chantepie S; Chehin RN; Ouidja MO; Papy-Garcia D
    Rev Neurol; 2017 Nov; 65(10):457-468. PubMed ID: 29130469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
    Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
    Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies.
    Foguel D; Silva JL
    Biochemistry; 2004 Sep; 43(36):11361-70. PubMed ID: 15350123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amyloid state and its association with protein misfolding diseases.
    Knowles TP; Vendruscolo M; Dobson CM
    Nat Rev Mol Cell Biol; 2014 Jun; 15(6):384-96. PubMed ID: 24854788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function.
    Leighton PL; Allison WT
    J Alzheimers Dis; 2016 Jul; 54(1):3-29. PubMed ID: 27392869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration.
    Maïza A; Chantepie S; Vera C; Fifre A; Huynh MB; Stettler O; Ouidja MO; Papy-Garcia D
    FEBS Lett; 2018 Dec; 592(23):3806-3818. PubMed ID: 29729013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of the molecular chaperone Hsp104 from yeast.
    Grimminger-Marquardt V; Lashuel HA
    Biopolymers; 2010 Mar; 93(3):252-76. PubMed ID: 19768774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The environmental dependency of protein folding best explains prion and amyloid diseases.
    Kelly JW
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):930-2. PubMed ID: 9448261
    [No Abstract]   [Full Text] [Related]  

  • 14. [New world of amyloid science].
    Lee YH; Ozawa D; Goto Y
    Seikagaku; 2009 Aug; 81(8):677-87. PubMed ID: 19803391
    [No Abstract]   [Full Text] [Related]  

  • 15. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases.
    Kelly JW
    Structure; 1997 May; 5(5):595-600. PubMed ID: 9195890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
    Zaman M; Khan AN; Wahiduzzaman ; Zakariya SM; Khan RH
    Int J Biol Macromol; 2019 Aug; 134():1022-1037. PubMed ID: 31128177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of chaperones in Parkinson's disease and prion diseases.
    Winklhofer KF; Tatzelt J
    Handb Exp Pharmacol; 2006; (172):221-58. PubMed ID: 16610362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein aggregation.
    Merlini G; Bellotti V; Andreola A; Palladini G; Obici L; Casarini S; Perfetti V
    Clin Chem Lab Med; 2001 Nov; 39(11):1065-75. PubMed ID: 11831622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process, Outcomes and Possible Elimination of Aggregation with Special Reference to Heme Proteins; Likely Remediations of Proteinopathies.
    Furkan M; Khan RH
    Curr Protein Pept Sci; 2020; 21(6):573-583. PubMed ID: 32013844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.